Literature DB >> 8375391

In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse.

R A Srivastava1, D Baumann, G Schonfeld.   

Abstract

Rats and mice are frequently used in studies of the regulation of lipoprotein metabolism. Although the species are closely related, they differ dramatically in the responses of their lipoproteins to estrogen administration. In rats, estrogens produce profound decreases in the levels of all plasma lipoproteins and this is attributed largely to estrogen-induced increases of hepatic low-density lipoprotein receptor (LDL-receptor) activity. Estrogens affect mouse plasma lipoproteins to a much lesser extent. Therefore, one of our aims was to compare the regulation of LDL-receptor gene expression in rats and mice at several potential loci of regulation. To assess the specificity of the estrogen effect, we also compared the responses of apolipoprotein AI (apoAI), apolipoprotein B (apoB), and beta-actin to the response of the LDL-receptor. In male Sprague Dawley rats given 17 beta-estradiol or 17 alpha-ethinyl estradiol at supraphysiological doses of 5 micrograms/g body mass/day, plasma total cholesterol and triacylglycerols fell to approximately 5% and approximately 50%, and, plasma apoAI and apoB fell to approximately 12% and approximately 16% of controls, respectively. By contrast, in male C3H/HeJ mice the above parameters dropped only to approximately 65% of controls and apoB concentrations rose to approximately 200% of controls. In rats, relative rates of LDL-receptor mRNA transcription (nuclear 'run-off' assay) and total hepatic, nuclear and polysomal LDL-receptor mRNA levels (RNase protection assay) increased by 1.5-2-fold, while synthesis of LDL-receptor protein on hepatic polysomes (in a wheat-germ translation system) increased 8-fold and LDL-receptor protein mass in hepatic plasma membranes increased 10-fold (by immunoblotting). In mouse liver, too, LDL-receptor mRNA levels increased 1.5-fold and the LDL-receptor mRNA transcription start sites in rat and mouse were found to be the same, but mouse LDL-receptor protein mass did not change, i.e. LDL-receptors of mice were similar to rat with respect to transcriptional regulation, but differed in their post-transcriptional control mechanisms. In rats, estrogen administration increased apoAI mRNA transcription rates 1.6-fold and also apoAI mRNA levels in total liver homogenates, nuclei and polysomes, (2-fold for each) consistent with transcriptional regulation. However, apoAI synthesis on total RNA increased less than apoAI mRNA, indicating that apoAI translational control mechanisms, at least in part, also regulate hepatic rates of apoAI production. ApoB mRNA transcription rates and levels showed small increases following estrogen administration. Hepatic beta-actin mRNA transcription and levels did not change.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375391     DOI: 10.1111/j.1432-1033.1993.tb18171.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

1.  Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms.

Authors:  R A Srivastava; E S Krul; R C Lin; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Richard W Browne; Audrey J Gaskins; Maurizio Trevisan; Anne Z Steiner; Julie L Daniels; Cuilin Zhang; Neil J Perkins; Jean Wactawski-Wende
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

3.  Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB.

Authors:  R A Srivastava; L Toth; N Srivastava; M E Hinsdale; N Maeda; A B Cefalu; M Averna; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

Review 4.  Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.

Authors:  Enrique F Schisterman; Sunni L Mumford; Lindsey A Sjaarda
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

5.  Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

Review 6.  Cardiovascular pharmacology of hormone replacement therapy.

Authors:  G M Rosano; G Panina
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

7.  Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat.

Authors:  K T Landschulz; R K Pathak; A Rigotti; M Krieger; H H Hobbs
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

8.  Variations in lipid levels according to menstrual cycle phase: clinical implications.

Authors:  Sunni L Mumford; Sonya Dasharathy; Anna Z Pollack; Enrique F Schisterman
Journal:  Clin Lipidol       Date:  2011-04-01

9.  Estrogen increases hepatic lipase levels in inbred strains of mice: a possible mechanism for estrogen-dependent lowering of high density lipoprotein.

Authors:  N Srivastava; P R Chowdhury; M Averna; R A Srivastava
Journal:  Mol Cell Biochem       Date:  2001-04       Impact factor: 3.396

10.  Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.

Authors:  Junga Lee; Richard C Scheri; Yuan Zhang; Lawrence R Curtis
Journal:  Toxicol Appl Pharmacol       Date:  2008-08-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.